PURPOSE: Etomidate and ketamine are hemodynamically stable induction agents often used to sedate critically ill patients during emergency endotracheal intubation. In 2015, quality improvement data from our hospital suggested a survival benefit at Day 7 from avoidance of etomidate in critically ill patients during emergency intubation. In this clinical trial, we hypothesized that randomization to ketamine instead of etomidate would be associated with Day 7 survival after emergency endotracheal intubation. METHODS: A prospective, randomized, open-label, parallel assignment, single-center clinical trial performed by an anesthesiology-based Airway Team under emergent circumstances at one high-volume medical center in the United States. 801 critically ill patients requiring emergency intubation were randomly assigned 1:1 by computer-generated, pre-randomized sealed envelopes to receive etomidate (0.2-0.3 mg/kg, n = 400) or ketamine (1-2 mg/kg, n = 401) for sedation prior to intubation. The pre-specified primary endpoint of the trial was Day 7 survival. Secondary endpoints included Day 28 survival. RESULTS: Of the 801 enrolled patients, 396 were analyzed in the etomidate arm, and 395 in the ketamine arm. Day 7 survival was significantly lower in the etomidate arm than in the ketamine arm (77.3% versus 85.1%, difference - 7.8, 95% confidence interval - 13, - 2.4, p = 0.005). Day 28 survival rates for the two groups were not significantly different (etomidate 64.1%, ketamine 66.8%, difference - 2.7, 95% confidence interval - 9.3, 3.9, p = 0.294). CONCLUSION: While the primary outcome of Day 7 survival was greater in patients randomized to ketamine, there was no significant difference in survival by Day 28.
PURPOSE: Etomidate and ketamine are hemodynamically stable induction agents often used to sedate critically ill patients during emergency endotracheal intubation. In 2015, quality improvement data from our hospital suggested a survival benefit at Day 7 from avoidance of etomidate in critically ill patients during emergency intubation. In this clinical trial, we hypothesized that randomization to ketamine instead of etomidate would be associated with Day 7 survival after emergency endotracheal intubation. METHODS: A prospective, randomized, open-label, parallel assignment, single-center clinical trial performed by an anesthesiology-based Airway Team under emergent circumstances at one high-volume medical center in the United States. 801 critically ill patients requiring emergency intubation were randomly assigned 1:1 by computer-generated, pre-randomized sealed envelopes to receive etomidate (0.2-0.3 mg/kg, n = 400) or ketamine (1-2 mg/kg, n = 401) for sedation prior to intubation. The pre-specified primary endpoint of the trial was Day 7 survival. Secondary endpoints included Day 28 survival. RESULTS: Of the 801 enrolled patients, 396 were analyzed in the etomidate arm, and 395 in the ketamine arm. Day 7 survival was significantly lower in the etomidate arm than in the ketamine arm (77.3% versus 85.1%, difference - 7.8, 95% confidence interval - 13, - 2.4, p = 0.005). Day 28 survival rates for the two groups were not significantly different (etomidate 64.1%, ketamine 66.8%, difference - 2.7, 95% confidence interval - 9.3, 3.9, p = 0.294). CONCLUSION: While the primary outcome of Day 7 survival was greater in patients randomized to ketamine, there was no significant difference in survival by Day 28.
Authors: Michael D April; Allyson Arana; Steven G Schauer; William T Davis; Joshua J Oliver; Andrea Fantegrossi; Shane M Summers; Joseph K Maddry; Ron M Walls; Calvin A Brown Journal: Acad Emerg Med Date: 2020-07-18 Impact factor: 3.451
Authors: Nathan Jerome Smischney; Wayne T Nicholson; Daniel R Brown; Alice Gallo De Moraes; Sumedh S Hoskote; Brian Pickering; Richard A Oeckler; Vivek N Iyer; Ognjen Gajic; Darrell R Schroeder; Philippe R Bauer Journal: J Trauma Acute Care Surg Date: 2019-10 Impact factor: 3.313
Authors: Nicholas M Mohr; Stephen G Pape; Dan Runde; Amy H Kaji; Ron M Walls; Calvin A Brown Journal: Acad Emerg Med Date: 2020-07-20 Impact factor: 3.451
Authors: Vincenzo Russotto; Sheila Nainan Myatra; John G Laffey; Elena Tassistro; Laura Antolini; Philippe Bauer; Jean Baptiste Lascarrou; Konstanty Szuldrzynski; Luigi Camporota; Paolo Pelosi; Massimiliano Sorbello; Andy Higgs; Robert Greif; Christian Putensen; Christina Agvald-Öhman; Athanasios Chalkias; Kristaps Bokums; David Brewster; Emanuela Rossi; Roberto Fumagalli; Antonio Pesenti; Giuseppe Foti; Giacomo Bellani Journal: JAMA Date: 2021-03-23 Impact factor: 56.272
Authors: Gerald Matchett; Omaira Azizad; Brian J Bravenec; Brian G Farrell; Dawood Nasir Journal: Intensive Care Med Date: 2022-03-31 Impact factor: 41.787
Authors: Thais Dias Midega; Renato Carneiro de Freitas Chaves; Carolina Ashihara; Roger Monteiro Alencar; Verônica Neves Fialho Queiroz; Giovana Roberta Zelezoglo; Luiz Carlos da Silva Vilanova; Guilherme Benfatti Olivato; Ricardo Luiz Cordioli; Bruno de Arruda Bravim; Thiago Domingos Corrêa Journal: Rev Bras Ter Intensiva Date: 2022 Apr-Jun